Cliff Asness's TRDA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 79,493 shares of Entrada Therapeutics, Inc. (TRDA) worth $1 M, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 7 quarters.
Based on 13F filings, Cliff Asness has maintained this position in TRDA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 53,239 shares. Largest reduction occurred in Q1 2025, reducing 24,060 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Entrada Therapeutics (TRDA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Entrada Therapeutics (TRDA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +53,239 | Add 202.78% | 79,493 | $12.62 |
| Q4 2025 | +12,263 | Add 87.65% | 26,254 | $10.28 |
| Q3 2025 | -21,629 | Reduce 60.72% | 13,991 | $5.80 |
| Q2 2025 | +4,701 | Add 15.20% | 35,620 | $6.72 |
| Q1 2025 | -24,060 | Reduce 43.76% | 30,919 | $9.04 |
| Q4 2024 | +15,511 | Add 39.30% | 54,979 | $17.29 |
| Q3 2024 | +39,468 | New Buy | 39,468 | $15.98 |
Cliff Asness's Entrada Therapeutics Investment FAQs
Cliff Asness first purchased Entrada Therapeutics, Inc. (TRDA) in Q3 2024, acquiring 39,468 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Entrada Therapeutics, Inc. (TRDA) for 7 quarters since Q3 2024.
Cliff Asness's largest addition to Entrada Therapeutics, Inc. (TRDA) was in Q1 2026, adding 79,493 shares worth $1 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 79,493 shares of Entrada Therapeutics, Inc. (TRDA), valued at approximately $1 M.
As of the Q1 2026 filing, Entrada Therapeutics, Inc. (TRDA) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Entrada Therapeutics, Inc. (TRDA) was 79,493 shares, as reported at the end of Q1 2026.